Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.
The suit alleges an army veteran’s diagnosis was held up for months due to errors with the electronic health record.
Veteran’s lawsuit alleges VA Oracle EHR delayed cancer diagnosis Read More »
Bering Limited, a London -based medical AI company, today announced it received US Food and Drug Administration (FDA) 510(k) clearance for its AI-powered chest X-Ray triage solution, ‘BraveCX’.
Bering Secures FDA Clearance for AI-Based Chest X-Ray Triage Solution Read More »
With the biopharma industry’s looming wave of gene therapy submissions and potential approvals, the senior senator is laying the groundwork for a legislative initiative to improve access to these expensive treatments.
Sen. Bill Cassidy Eyes Legislation to Improve Access to Gene Therapies Read More »
CARGO Therapeutics, Inc. today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
CARGO Therapeutics Announces Scientific Advisory Board Read More »
Tandem Diabetes Care, Inc. today announced the launch of updated t:slim X2™ insulin pump software with Dexcom G7 Continuous Glucose Monitoring (CGM) integration in the United States.
Zomedica Corp. today announced the presentation of new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners (AAEP) annual meeting in San Diego, California.
Outlook Therapeutics, Inc. today announced a realignment of resources.
Outlook Therapeutics® Announces Strategic Organizational Realignment Read More »
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays.
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays Read More »
Sera Prognostics Inc. today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis.
